RxDoctor Payments Data

Gina Ragusa

Family · Gonzales, LANPI 1144575432

Payments from drug & device makers

$9,302in general payments, 2019–2025

Across 537 payments — averaging $17.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Takeda Pharmaceuticals U.S.A., Inc.$882
  • Bristol Myers Squibb$740
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$687
  • Gilead$440
  • Madrigal Pharmaceuticals$406
  • plus $3K from 21 others

What the payments were for

  • Food & beverage$9,277100%
  • Education$250%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,302 in reported general payments places this provider in the 95th percentile of 3,610 family providers in Louisiana.

See all family providers in Louisiana

Medicare billing

Part B allowed, 2024
$15,197
Medicare patients
123
Services billed
145

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide89$57,444
CreonLipase/Protease/Amylase26$48,809
IbsrelaTenapanor Hcl12$21,116
ZenpepLipase/Protease/Amylase17$18,487
TrulancePlecanatide17$9,564
MotegrityPrucalopride Succinate15$7,925
Lubiprostone23$1,702
Esomeprazole Magnesium98$1,631
Pantoprazole Sodium151$1,106
Colestipol Hcl18$1,087
Sucralfate13$714
Famotidine23$680
Omeprazole51$526
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl13$227

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$2,896$106,253115 claims
Ardelyx, Inc.Ibsrela$189$21,11612 claims
Aimmune Therapeutics, Inc.Zenpep$165$18,48717 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$687$9,56417 claims
Takeda Pharmaceuticals U.S.A., Inc.Motegrity$882$7,92515 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,610 family providers in Louisiana.

Other family in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →